Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA To Track Monkeypox Medicines Stock & Boost Emergency Task Force Output

Executive Summary

The European Medicines Agency is taking more actions to tackle monkeypox now that the disease has been declared a public health emergency.

You may also be interested in...



Cipla Uncorks Peptide Injectables Pipeline

Cipla readies scale-up in peptide injectables with five filings in the US and gears for upcoming high-value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.

Cipla Uncorks Peptide Injectables Pipeline, Eyes Partnering For Monkeypox

Cipla readies scale up in peptide injectables with five filings in the US and gears for upcoming high value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.

Janssen’s Multiple Myeloma Drug Among 11 Products To Get EMA Thumbs Up

The European Medicines Agency has cleared the decks for the pan-EU approval of nearly a dozen new drugs. Tecvayli is headed for a conditional approval, while Nulibry is slated to get marketing authorization under exceptional circumstances. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel